We have two drug discovery platforms for the creation of novel drug candidates. Our drug candidates are composed of synthetic RNA and DNA.
The first platform involves creating synthetic RNA- and DNA-based compounds to modulate immune responses through endosomal Toll-like Receptors 3, 7, 8, and 9. We believe that the modulation of immune responses through TLRs provides a rationale for developing drug candidates to treat a broad range of diseases, including autoimmune and inflammatory diseases, cancer, and respiratory diseases.
The second platform involves gene-silencing, which leads to inhibition of expression of disease-associated proteins. We believe that our Gene Silencing Oligonucleotide (GSO) technology provides us with a platform from which drug candidates for a variety of disease indications can be developed.
We are focusing our development efforts on the treatment of autoimmune and inflammatory diseases. We are seeking to enter into collaborative alliances with third parties to advance our additional TLR research programs in the treatment of cancer, hematological malignancies, and respiratory diseases, and the use of TLR3 agonists as vaccine adjuvants and to advance applications of our GSO technology.